Research Study

An Open-label Study of Dupilumab in Patients With Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials
Principal Investigator 
Vincent C. Ho

Overview

Body Locations and Systems 
Dermatitis
ClinicalTrials.gov# 
NCT01949311
Status 
Closed to Recruitment
Study Start/End 
Jun 2, 2014 to Oct 30, 2018
Locations 
Vancouver General Hospital
Name/Title 
Jaspal Mor, Study Coordinator
Phone 
604-875-5296
Purpose of Study 

This is an open label extension study for patients who participated in placebo-controlled dupilumab atopic dermatitis (AD) trials. The study primarily evaluates long term safety (adverse events) and immunogenicity. Efficacy parameters are based on Investigator Global Assessment (IGA), Eczema Area and Severity Index (EASI) and the Pruritus Numerical Rating Scale (NRS).

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.